CTIS2022-502759-70-01招募中1 期
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies. - D6900C00001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Signed informed consent, If clinically feasible, must consent to provide fresh tumor biopsies in screening, Relapsed/metastatic solid tumors with prior adequate SoC therapy for the tumor type and stage, Additional Inclusion Criteria for Part A (Dose Escalation): Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, CCA, or endometrial cancer which is progressing, Additional Inclusion Criteria for Part A (Dose Escalation) PDx backfill cohort criteria: At least 1 tumor suitable for biopsy and consent to having fresh biopsies, Consent to provide adequate baseline tumor sample, = 18 years, ECOG PS 0-1, Measurable disease per RECIST v1.1, Life expectancy = 12 weeks, Adequate organ and marrow function as described in the protocol, Compliance with the protocol, Contraceptive use, Additional Inclusion Criteria for Part B (Dose Expansion): Participants must have histologically or cytologically confirmed metastatic or locally advanced and recurrent disease for the respective cohort, Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B1 (BTC): Histologically/cytologically verified, non-resectable, recurrent, or metastatic biliary tract carcinoma, Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B2 (Ovarian cancer): Histologically confirmed diagnosis of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B2A Platinum-resistant disease: Prior PARP inhibitors or bevacizumab if eligible, Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B2B Platinum-sensitive disease: Platinum-sensitive disease is defined as radiographic progression greater than 6 months from last dose of most recent platinum therapy., Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B2B Platinum-sensitive disease: Prior PARP inhibitors or bevacizumab if eligible, Additional Inclusion Criteria for Part B (Dose Expansion) - Cohort B3 (HER2-negative breast cancer) [IHC: 0, 1+, 2+/ISH-] Cohort B3A (HR+ HER2-negative breast cancer): HER2-negative [ICH: 0, 1+, 2+/ISH-] and HR+, Adequate venous access, Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B3B (TNBC): HER2-negative [IHC: 0, 1+, 2+/ISH-] and HR-, Additional Inclusion Criteria for Part B (Dose Expansion) Cohort B3C (HR±, HER2-negative breast cancer): HER2-negative [IHC: 0, 1+, 2+/ISH-], HR+ or
排除标准
- •Spinal cord compression or a history of leptomeningeal carcinomatosis., Previous enrollment and treatment in the present study., Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids., Additional Exclusion Criteria for Part B Dose Expansion Cohorts B2A and B2B: Low-grade/borderline ovarian tumors are not eligible., Treatment with any of the following within the protocol defined time periods prior to the first dose of study intervention: nitrosourea or mitomycin C, any investigational agents, cytotoxic treatment, non-cytotoxic drugs, biological products including immuno-oncology agents, radiotherapy, major surgery., Unresolved toxicities of Grade = 2 from prior therapy (excluding vitiligo, alopecia, controlled endocrine disorders, and chemotherapy-induced Grade 2 neuropathy)., Active infection, including tuberculosis and infections with HBV, HCV or HIV. Certain exceptions apply for past or resolved HBV/HCV infections., History of ILD/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out., Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses., History of another primary malignancy, with the exceptions listed in the protocol., Participants with any of the cardiac criteria detailed in the protocol., Uncontrolled intercurrent illness within the last 12 months., Has substance abuse or any other medical conditions., Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention. Exclusions apply for COVID-19 vaccines., Currently pregnant, lactating, breastfeeding, or intend to become pregnant during the study., Concurrent enrollment in another study, unless it is an observational study or during the follow-up period of an interventional study., Participants with a known hypersensitivity to study intervention or any of its excipients., Involvement in the planning and/or conduct of the study., Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
研究者
相似试验
进行中（未招募）
1 期
Master Protocol of Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumoursvarious Advanced/Metastatic solid tumour types- Endometrial Cancer - Gastric Cancer - Ovarian Cancer- Metastatic castration-resistant prostate cancer- Colorectal cancerMedDRA version: 12.0Level: HLGTClassification code 10007129Term: Cancer-related morbiditiesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000776-19-FRAstraZeneca AB541
进行中（未招募）
1 期
Master Protocol of Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid TumoursEUCTR2022-000776-19-PLAstraZeneca AB670
招募中
1 期
Master Protocol of Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid TumoursEndometrial CancerMetastatic Castration-resistant Prostate CancerUrothelial CancerBiliary Tract CancerMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2Ovarian CancerGastric CancerColorectal CancerCTIS2023-509436-26-00AstraZeneca AB773
招募中
2 期
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)Endometrial CAGastric CAProstate CAOvarian CAColorectal CAUrothelial CABiliary Tract CAJPRN-jRCT2031220404Inoguchi Akihiro670
撤回
不适用
A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem cell transplantatioNL-OMON48950ovartis4